Project Grant R43CA302284
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
The Woodlands, TX 77382, USA
Similar Awards
- Federal Project Grant Award Summary Intra Therapeutics, LLC received a $398,039 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 18, 2025, with completion targeted for August 31, 2026. The award supports the development and optimization of XCSGEL-IL12, an injectable hydrogel-based immunotherapy designed for localized treatment of triple-negative breast cancer. The project focuses on formulating interleukin-12...
- The National Cancer Institute awarded $400,000 to Intra Therapeutics, Inc. on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop IT-001, a localized cancer immunotherapy for intratumoral injection. IT-001 combines interleukin-12 (IL-12) with a proprietary injectable hydrogel designed to retain the cytokine within tumors for up to four weeks while minimizing systemic toxicity. Preclinical data demonstrate that a single IT-001 treatment produces complete...
- The National Cancer Institute awarded Nanocan Therapeutics Corporation $2,996,343 on September 24, 2025, to conduct the first clinical trial of the Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel for treatment of advanced cervical cancer under the Cancer Treatment Research program (CFDA 93.395). The LIFE gel is a biocompatible, biodegradable immunotherapeutic administered locally in conjunction with hypo-fractionated radiotherapy. The technology extends local radiotherapy's use from...
- The National Institutes of Health National Cancer Institute awarded Saros Therapeutics Inc. $1.164 million on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to demonstrate the safety and combination therapy potential of a novel nanoparticle delivery system for immuno-oncology. Saros Therapeutics is developing a manganese-containing nanoparticle platform, designated SMP, that incorporates a STING agonist to activate the cGAS-STING pathway in dendritic cells and...
- The National Institutes of Health National Cancer Institute awarded Absco Therapeutics, Inc. $406,500 on September 17, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop an intratumoral delivery system for enhancing solid tumor immunotherapy. Absco Therapeutics is advancing the Oncolymer platform, a thermoresponsive hydrogel technology based on PLGA and PEG polymer that transforms from room-temperature liquid to a solidified depot upon injection. The system delivers a...
- The National Cancer Institute awarded Vesicle Therapeutics Inc. $400,000 on September 16, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a targeted antisense oligonucleotide therapy for head and neck squamous cell carcinoma. Vesicle Therapeutics is synthesizing and evaluating a thiomorpholino-based antisense oligonucleotide designed to selectively inhibit the oncogenic STAT3A isoform while preserving the tumor-suppressive STAT3B isoform. The Phase I project...
- The National Cancer Institute awarded Twin Peaks Bio, Inc. $398,704 on September 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct lead selection studies of novel antisense oligonucleotide therapies for head and neck squamous cell carcinoma immunotherapy. Twin Peaks Bio will develop bi-specific conjugate molecules that pair STAT3 antisense oligonucleotides with synthetic TLR9 agonists (CPG DNA) for targeted delivery to tumor-associated myeloid cells. The approach aims...
- The National Cancer Institute awarded Lipo-Immuno TECH LLC $348,352 on August 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a C18-ceramide analog drug targeting head and neck squamous cell carcinoma. The recipient is developing LCL768, a first-in-class compound that conjugates C18-ceramide with pyridinium to selectively accumulate in HNSCC mitochondria, bind LC3B, and recruit autophagosomes, with selenite included to induce DRP1 activation and lethal mitophagy....
- The National Cancer Institute awarded The Broad Institute, Inc. $742,382 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate PTPN2 inhibition combined with STING agonism as a therapeutic approach to enhance immune-mediated control of head and neck squamous cell carcinoma. The research will examine the mechanism by which PTPN2 inhibition elevates STING levels in tumor cells and how the signaling pathways engaged by both therapies synergistically activate...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...